Effect of Low-Dose Triptolide and Sorafenib Alone and Their Combination on AML Cell Line MV411 and the Pathway of STAT5.
10.19746/j.cnki.issn.1009-2137.2019.04.016
- Author:
Xue WANG
1
;
Liang-Ming MA
2
;
Tao WANG
3
;
Wei-Wei TIAN
3
;
Yu-Jin LU
3
Author Information
1. Shanxi Medical University, Taiyuan 030001,Shanxi Province,China.
2. Department of Hematology,Shanxi Dayi Hospital Affiliated to Shanxi Medical University, Taiyuan 030032,Shanxi Province,China,E-mail: maliangming620928@163.com.
3. Department of Hematology,Shanxi Dayi Hospital Affiliated to Shanxi Medical University, Taiyuan 030032,Shanxi Province,China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Cell Line, Tumor;
Diterpenes;
Epoxy Compounds;
Humans;
Leukemia, Myeloid, Acute;
Phenanthrenes;
STAT5 Transcription Factor;
Sorafenib;
fms-Like Tyrosine Kinase 3
- From:
Journal of Experimental Hematology
2019;27(4):1088-1093
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effects of inhibiting proliferation and inducing apoptosis of low-dose triptolide and sorafenib alone or in combination on FLT3-ITD acute myeloid leukemia cell line MV4-11 and STAT5 pathway.
METHODS:The MV4-11 cells were treated with low dose triptolide(IC) and sorafenib(IC) alone or in combination for 48 hours. The cell proliferation and inhibition were detected by using CCK-8 kit, the cell apoptosis was detected by flow cytometry, the expression of FLT3,STAT5 in mRNA and protein levels was detected by RT-PCR and Western blot respectively.
RESULTS:The treatment of MV4-11 cells with low dose triptolide and sorafenib alone and in combination for 48 hours could inhibit cell proliferation and induce cell apoptosis, moreover the inhibitory rate and apoptotic rate of MV4-11 cells in drug-combination group both were higher than those in single drug group. The mRNA expression and protein expression of FLT3,STAT5 signaling pathway in drug combination group were significantly lower than those in single drug group.
CONCLUSION:Low-dose triptolide combined with sorafenib can synergistically inhibit the proliferation and induce the apoptosis of MV4-11 cells, which may be related with the inhibition of FLT3 and STAT5 pathway.
